|
1
|
Bellahcène A, Castronovo V, Ogbureke KU,
Fisher LW and Fedarko NS: Small integrin-binding ligand N-linked
glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat
Rev Cancer. 8:212–226. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang Y, Forootan SS, Kamalian L, et al:
Suppressing tumourigenicity of prostate cancer cells by inhibiting
osteopontin expression. Int J Oncol. 38:1083–1091. 2011.PubMed/NCBI
|
|
3
|
Zheng J, Hou ZB and Jiao NL: Effects of
osteopontin downregulation on the growth of prostate cancer PC-3
cells. Mol Med Rep. 4:1225–1231. 2011.PubMed/NCBI
|
|
4
|
He B, Mirza M and Weber GF: An osteopontin
splice variant induces anchorage independence in human breast
cancer cells. Oncogene. 25:2192–2202. 2006. View Article : Google Scholar
|
|
5
|
Gimba ER and Tilli TM: Human osteopontin
splicing isoforms: known roles, potential clinical applications and
activated signaling pathways. Cancer Lett. 331:11–17. 2013.
View Article : Google Scholar
|
|
6
|
Puzone R, Paleari L, Montefiore F, et al:
Osteopontin plasma level does not detect prostate cancer in
patients referred for diagnostic prostate biopsy. Int J Biol
Markers. 25:200–206. 2010.PubMed/NCBI
|
|
7
|
Thoms JW, Dal Pra A, Anborgh PH, et al:
Plasma osteopontin as a biomarker of prostate cancer aggression:
relationship to risk category and treatment response. Br J Cancer.
107:840–846. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Weber GF, Lett GS and Haubein NC:
Osteopontin is a marker for cancer aggressiveness and patient
survival. Br J Cancer. 103:861–869. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Weber GF, Lett GS and Haubein NC:
Categorical meta-analysis of Osteopontin as a clinical cancer
marker. Oncol Rep. 25:433–441. 2011. View Article : Google Scholar
|
|
10
|
Tilli TM, Mello KD, Ferreira LB, et al:
Both osteopontin-c and osteopontin-b splicing isoforms exert
pro-tumorigenic roles in prostate cancer cells. Prostate.
72:1688–1699. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tilli TM, Thuler LC, Matos AR, et al:
Expression analysis of osteopontin mRNA splice variants in prostate
cancer and benign prostatic hyperplasia. Exp Mol Pathol. 92:13–19.
2012. View Article : Google Scholar
|
|
12
|
Martinez HD, Hsiao JJ, Jasavala RJ,
Hinkson IV, Eng JK and Wright ME: Androgen-sensitive microsomal
signaling networks coupled to the proliferation and differentiation
of human prostate cancer cells. Genes Cancer. 2:956–978. 2011.
View Article : Google Scholar
|
|
13
|
Takayama K, Tsutsumi S, Katayama S, et al:
Integration of cap analysis of gene expression and chromatin
immunoprecipitation analysis on array reveals genome-wide androgen
receptor signaling in prostate cancer cells. Oncogene. 30:619–630.
2011. View Article : Google Scholar
|
|
14
|
Liu X, Choi RY, Jawad SM and Arnold JT:
Androgen-induced PSA expression requires not only activation of AR
but also endogenous IGF-I or IGF-I/PI3K/Akt signaling in human
prostate cancer epithelial cells. Prostate. 71:766–777. 2011.
View Article : Google Scholar :
|
|
15
|
Bitting RL and Armstrong AJ: Targeting the
PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
Endocr Relat Cancer. 20:R83–R99. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Terracciano D, Mazzarella C, Di Carlo A,
et al: Effects of the ErbB1/ErbB2 kinase inhibitor GW2974 on
androgen-independent prostate cancer PC-3 cell line growth and NSE,
chromogranin A and osteopontin content. Oncol Rep. 24:213–217.
2010.PubMed/NCBI
|
|
17
|
Zhu H and Garcia JA: Targeting the adrenal
gland in castration-resistant prostate cancer: a case for
orteronel, a selective CYP-17 17,20-lyase inhibitor. Curr Oncol
Rep. 15:105–112. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Elo TD, Valve EM, Seppänen JA, et al:
Stromal activation associated with development of prostate cancer
in prostate-targeted fibroblast growth factor 8b transgenic mice.
Neoplasia. 12:915–927. 2010.PubMed/NCBI
|
|
19
|
Angelucci A, Festuccia C, Gravina GL, et
al: Osteopontin enhances the cell proliferation induced by the
epidermal growth factor in human prostate cancer cells. Prostate.
59:157–166. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tilli TM, Bellahcène A, Castronovo V and
Gimba ER: Changes in the transcriptional profile in response to
overexpression of the osteopontin-c splice isoform in ovarian
(OvCar-3) and prostate (PC-3) cancer cell lines. BMC Cancer.
14:4332014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ngan S, Stronach EA, Photiou A, Waxman J,
Ali S and Buluwela L: Microarray coupled to quantitative RT-PCR
analysis of androgen-regulated genes in human LNCaP prostate cancer
cells. Oncogene. 28:2051–2063. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mattila MM and Härkönen PL: Role of
fibroblast growth factor 8 in growth and progression of hormonal
cancer. Cytokine Growth Factor Rev. 18:257–266. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ferreira LB, Palumbo A, de Mello KD, et
al: PCA3 noncoding RNA is involved in the control of
prostate-cancer cell survival and modulates androgen receptor
signaling. BMC Cancer. 12:5072012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Flores O, Wang Z, Knudsen KE and Burnstein
KL: Nuclear targeting of cyclin-dependent kinase 2 reveals
essential roles of cyclin-dependent kinase 2 localization and
cyclin E in vitamin D-mediated growth inhibition. Endocrinology.
151:896–908. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rae JM, Johnson MD, Cordero KE, et al:
GREB1 is a novel androgen-regulated gene required for prostate
cancer growth. Prostate. 66:886–894. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lilja H: Biology of prostate-specific
antigen. Urology. 62(Suppl 1): 27–33. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen YW, Lee MS, Lucht A, et al: TMPRSS2,
a serine protease expressed in the prostate on the apical surface
of luminal epithelial cells and released into semen in prostasomes,
is misregulated in prostate cancer cells. Am J Pathol.
176:2986–2996. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tomlins SA, Laxman B, Varambally S, et al:
Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia.
10:177–188. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li H, Xu LL, Masuda K, et al: A feedback
loop between the androgen receptor and a NEDD4-binding protein,
PMEPA1, in prostate cancer cells. J Biol Chem. 283:28988–28995.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Richter E, Masuda K, Cook C, et al: A role
for DNA methylation in regulating the growth suppressor PMEPA1 gene
in prostate cancer. Epigenetics. 2:100–109. 2007. View Article : Google Scholar
|
|
31
|
Mattsson JM, Laakkonen P, Stenman UH and
Koistinen H: Antiangiogenic properties of prostate-specific antigen
(PSA). Scand J Clin Lab Invest. 69:447–451. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Guo Y, Pili R and Passaniti A: Regulation
of prostate-specific antigen gene expression in LNCaP human
prostatic carcinoma cells by growth, dihydrotestosterone, and
extracellular matrix. Prostate. 24:1–10. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sica G, Iacopino F, Settesoldi D and
Zelano G: Effect of leuprorelin acetate on cell growth and
prostate-specific antigen gene expression in human prostatic cancer
cells. Eur Urol. 35(Suppl 1): 2–8. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Valdez CD, Davis JN, Odeh HM, et al:
Repression of androgen receptor transcription through the
E2F1/DNMT1 axis. PloS One. 6:e251872011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shiota M, Yokomizo A and Naito S:
Increased androgen receptor transcription: a cause of
castration-resistant prostate cancer and a possible therapeutic
target. J Mol Endocrinol. 47:R25–R41. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hou X, Li Z, Huang W, et al:
Plk1-dependent microtubule dynamics promotes androgen receptor
signaling in prostate cancer. Prostate. 73:1352–1363. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Baena E, Shao Z, Linn DE, et al: ETV1
directs androgen metabolism and confers aggressive prostate cancer
in targeted mice and patients. Genes Dev. 27:683–698. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Patki M, Chari V, Sivakumaran S, Gonit M,
Trumbly R and Ratnam M: The ETS domain transcription factor ELK1
directs a critical component of growth signaling by the androgen
receptor in prostate cancer cells. J Biol Chem. 288:11047–11065.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chun JY, Nadiminty N, Dutt S, et al:
Interleukin-6 regulates androgen synthesis in prostate cancer
cells. Clin Cancer Res. 15:4815–4822. 2009. View Article : Google Scholar : PubMed/NCBI
|
